Literature DB >> 28537447

Hypocretin measurement: shelf age of radioimmunoassay kit, but not freezer time, influences assay variability.

Glenda Keating1, Donald L Bliwise1,2, Prabhjyot Saini1, David B Rye1,2, Lynn Marie Trotti1,2.   

Abstract

The hypothalamic peptide hypocretin 1 (orexin A) may be assayed in cerebrospinal fluid to diagnose narcolepsy type 1. This testing is not commercially available, and factors contributing to assay variability have not previously been comprehensively explored. In the present study, cerebrospinal fluid hypocretin concentrations were determined in duplicate in 155 patient samples, across a range of sleep disorders. Intra-assay variability of these measures was analyzed. Inter-assay correlation between samples tested at Emory and at Stanford was high (r = 0.79, p < 0.0001). Intra-assay correlation between samples tested in duplicate in our center was also high (r = 0.88, p < 0.0001); intra-assay variability, expressed as the difference between values as a percentage of the higher value, was low at 9.4% (SD = 7.9%). Although both time the sample spent in the freezer (r = 0.16, p = 0.04) and age of the kit used for assay (t = 3.64, p = 0.0004) were significant predictors of intra-kit variability in univariate analyses, only age of kit was significant in multivariate linear regression (F = 4.93, p = 0.03). Age of radioimmunoassay kit affects intra-kit variability of measured hypocretin values, such that kits closer to expiration exhibit significantly more variability.

Entities:  

Keywords:  Assay; cerebrospinal fluid; immunoassay; narcolepsy; sleep wake disorders

Mesh:

Substances:

Year:  2017        PMID: 28537447      PMCID: PMC5558786          DOI: 10.1080/00365513.2017.1325928

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity.

Authors:  L de Lecea; T S Kilduff; C Peyron; X Gao; P E Foye; P E Danielson; C Fukuhara; E L Battenberg; V T Gautvik; F S Bartlett; W N Frankel; A N van den Pol; F E Bloom; K M Gautvik; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

2.  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.

Authors:  Emmanuel Mignot; Gert Jan Lammers; Beth Ripley; Michele Okun; Sonia Nevsimalova; Sebastiaan Overeem; Jitka Vankova; Jed Black; John Harsh; Claudio Bassetti; Harald Schrader; Seiji Nishino
Journal:  Arch Neurol       Date:  2002-10

3.  Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.

Authors:  Christian R Baumann; Yves Dauvilliers; Emmanuel Mignot; Claudio L Bassetti
Journal:  Eur Neurol       Date:  2004-07-13       Impact factor: 1.710

4.  Clinical course of H1N1-vaccine-related narcolepsy.

Authors:  Tomi Sarkanen; Anniina Alakuijala; Markku Partinen
Journal:  Sleep Med       Date:  2015-11-25       Impact factor: 3.492

5.  The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns.

Authors:  Leonoor Wijnans; Coralie Lecomte; Corinne de Vries; Daniel Weibel; Cormac Sammon; Anders Hviid; Henrik Svanström; Ditte Mølgaard-Nielsen; Harald Heijbel; Lisen Arnheim Dahlström; Jonas Hallgren; Par Sparen; Poul Jennum; Mees Mosseveld; Martijn Schuemie; Nicoline van der Maas; Markku Partinen; Silvana Romio; Francesco Trotta; Carmela Santuccio; Angelo Menna; Giuseppe Plazzi; Keivan Kaveh Moghadam; Salvatore Ferro; Gert Jan Lammers; Sebastiaan Overeem; Kari Johansen; Piotr Kramarz; Jan Bonhoeffer; Miriam C J M Sturkenboom
Journal:  Vaccine       Date:  2012-12-16       Impact factor: 3.641

6.  CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway.

Authors:  Mona Skard Heier; Tatiana Evsiukova; Steinar Vilming; Michaela D Gjerstad; Harald Schrader; Kaare Gautvik
Journal:  Sleep       Date:  2007-08       Impact factor: 5.849

7.  Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors.

Authors:  David B Rye; Donald L Bliwise; Kathy Parker; Lynn Marie Trotti; Prabhjyot Saini; Jacqueline Fairley; Amanda Freeman; Paul S Garcia; Michael J Owens; James C Ritchie; Andrew Jenkins
Journal:  Sci Transl Med       Date:  2012-11-21       Impact factor: 17.956

8.  From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid.

Authors:  Christophe Hirtz; Jérôme Vialaret; Audrey Gabelle; Nora Nowak; Yves Dauvilliers; Sylvain Lehmann
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

  8 in total
  2 in total

1.  Hypocretin-1 measurements in cerebrospinal fluid using radioimmunoassay: within and between assay reliability and limit of quantification.

Authors:  Adrienne Elisabeth van der Hoeven; Kevin van Waaij; Denise Bijlenga; Frederik Willem Cornelis Roelandse; Sebastiaan Overeem; Jaap Adriaan Bakker; Rolf Fronczek; Gert Jan Lammers
Journal:  Sleep       Date:  2022-07-11       Impact factor: 6.313

2.  Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes.

Authors:  Lynn Marie Trotti; Donald L Bliwise; Glenda L Keating; David B Rye; William T Hu
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2021-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.